论文部分内容阅读
目的探讨瑞舒伐他汀不同给药剂量对急性心肌梗死患者心肌纤维化及心室重构的影响。方法抽取2014年3月至2015年12月符合研究选取标准的92例急性心肌梗死患者,根据用药剂量不同分为研究组和对照组,每组46例。研究组采用高剂量瑞舒伐他汀,对照组采用低剂量瑞舒伐他汀。对比治疗前后两组N末端脑钠肽前体(NT-pro BNP)、基质金属蛋白酶-9(MMP-9)、半乳凝素-3(Gal-3)水平变化情况及心功能相关指标[左室舒张期末内径(LVEDD)、左室收缩期末内径(LVESD)、左室舒张末期容积(LVEDV)、左室收缩末期内径(LVESV)、左室射血分数(LVEF)]水平变化情况。结果治疗前两组NT-pro BNP、MMP-9、Gal-3、LVEDD、LVESD、LVEDV、LVESV、LVEF水平比较差异未见统计学意义(P>0.05)。研究组治疗后NT-pro BNP、MMP-9、Gal-3、LVEDD、LVESD、LVEDV、LVESV、LVEF明显优于对照组,差异有统计学意义(P<0.05)。结论高剂量瑞舒伐他汀可更有效改善急性心肌梗死患者心肌纤维化及心室重构,提高心功能,值得推广。
Objective To investigate the effect of rosuvastatin administered at different doses on myocardial fibrosis and ventricular remodeling in patients with acute myocardial infarction. Methods A total of 92 patients with acute myocardial infarction who met the criteria of study selection from March 2014 to December 2015 were divided into study group and control group according to different dosage, 46 cases in each group. The study group used high-dose rosuvastatin, while the control group used low-dose rosuvastatin. The changes of N-terminal pro-brain natriuretic peptide (NT-pro BNP), matrix metalloproteinase-9 (MMP-9) and galectin-3 (Gal-3) (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic diameter (LVESV) and left ventricular ejection fraction (LVEF) Results There were no significant differences in the levels of NT-pro BNP, MMP-9, Gal-3, LVEDD, LVESD, LVEDV, LVESV and LVEF between the two groups before treatment (P> 0.05). The levels of NT-pro BNP, MMP-9, Gal-3, LVEDD, LVESD, LVEDV, LVESV and LVEF in the study group were significantly better than those in the control group (P <0.05). Conclusion High-dose rosuvastatin may be more effective in improving myocardial fibrosis and ventricular remodeling in patients with acute myocardial infarction, improve cardiac function, it is worth promoting.